Stories
Symbiotec Pharmalab's Q1 Profit Halves Amid New Business Costs
- •Symbiotec Pharmalab's Q1 net profit fell by over 50% to ₹14.1 crore, primarily due to expenses from new businesses yet to generate revenue.
- •Consolidated revenue increased to ₹218.2 crore, but EBITDA dropped to ₹45.2 crore, reflecting the impact of ₹23 crore in operating costs and ₹12 crore in depreciation from new ventures.
- •The core Active Pharmaceutical Ingredients (API) business showed steady growth, with operating revenue up to ₹215.3 crore and EBITDA at ₹65.8 crore, maintaining strong gross and EBITDA margins.
- •The company is advancing in complex injectables with a licensing agreement for two dual chamber vial products in the US and filed its first ANDA, with a second planned for early Q4 FY27.
- •Symbiotec is investing significantly in new businesses, with ₹1,000 crore of its ₹1,666 crore capex allocated to new revenue-generating ventures, expected to start generating income within 6-12 months.
Key Questions Answered
Symbiotec Pharmalab's consolidated net profit dropped to ₹14.1 crore in Q1 FY27 from ₹29.9 crore a year earlier. This decline occurred because expenses and operating costs from new businesses that are not yet generating revenue offset the steady growth seen in its core API business.
Symbiotec Pharmalab recently completed four major regulatory audits. EU-GMP audits at its Rau and Pithampur plants in March 2026 resulted in approval certificates, while a USFDA audit at Rau in March-April 2026 yielded an establishment inspection report (EIR), with the Pithampur USFDA audit report still awaited.
Symbiotec Pharmalab estimates a total gross capex of about ₹1,666 crore by the end of FY27. Out of this amount, 61% or ₹1,000 crore has been invested in new revenue-generating businesses, with revenue for the majority of these new capacities expected to begin in the next 6-12 months.
